MAM
KYMR icon

Marquette Asset Management’s Kymera Therapeutics KYMR Stock Holding History

Marquette Asset Management’s Portfolio KYMR Stock Details KYMR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$689 Hold
6
– – ﹤0.01% 763
2026
Q1 		$500 Buy
+6
New +$475 ﹤0.01% 755

Other funds holding KYMR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return

Marquette Asset Management's KYMR Position: Q2 2026 in Review

Marquette Asset Management held its Kymera Therapeutics (KYMR) position steady in Q2 2026 at 6 shares worth $689. The position accounts for ﹤0.01% of the portfolio, ranked #763.

Marquette Asset Management first reported a position in KYMR in Q1 2026 and has held it in 2 quarters since. 276 funds tracked by Wall St. Rank hold KYMR as of Q2 2026.

  • Marquette Asset Management held 6 shares of Kymera Therapeutics worth $689 as of Q2 2026.
  • Marquette Asset Management left its Kymera Therapeutics share count unchanged in Q2 2026.
  • Kymera Therapeutics made up ﹤0.01% of Marquette Asset Management's portfolio in Q2 2026, its #763 holding.
  • Marquette Asset Management first reported a position in Kymera Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • 276 funds tracked by Wall St. Rank held Kymera Therapeutics as of Q2 2026.

Based on Marquette Asset Management's 13F filing for Q2 2026, filed 9 Jul 2026.